Yeah non-inferiority is what you try to show for regulatory reasons. Head-to-heads are done for commercial reasons.
It's investigator-sponsored so the burden on CU6 financially will likely be minimal (we don't know the terms of the agreement). Usually what happens is the pharma company will supply product free of charge, or supply grants to help with the medical writing and publication of the data. Far less expensive than running the trial internally, yet potentially a large return. Smart from an ROI perspective if you are confident in the result.
The alternative was not providing any support to the investigator, which isn't great if you're trying to maintain relationships with KOLs, particularly one on your advisory board.
CU6 Price at posting:
$6.39 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)